On May 1, 2020, Harvard Bioscience, Inc. (the “Company”) eliminated the position of Executive Vice President, Cellular and Molecular Technologies in connection with the restructuring of its organization and terminated the employment of Yash Singh. Mr. Singh’s departure is a termination without cause under his Employment Agreement with the Company dated October 31, 2019 (the “Employment Agreement”). As a condition to his receipt of the severance benefits set forth in his Employment Agreement, Mr. Singh must sign and not revoke the Company’s standard general release, which includes a waiver and full release of claims against the Company.